Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will be a great movie for HHSE. GETTING GRACE -
opens in theatres March 23, and is already proving to be the company's top theatrical title, probably of all time (several "sneak peek" screenings have already occurred and SOLD OUT, with literally thousands of tickets cumulatively already sold!). This title deserves two or three mega-blogs. But for now, we'll include just a few images and a link or two.
Trailer # 1 (long version):
You are correct sir. HHSE has reached a significant turning point in the company's history!
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
Excellent Head Clown
SELDOM DOES A 30+ CENT STOCK TRADE AT LESS THAN 2 CENTS. AUDIT, UPLIST, SONY, MOTHER GOOSE, MELTDOWN, ETC, WILL TAKE HHSE PPS TO TRUE VALUE.
HHSE -- NO DILUTION in over 2.5 years!
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
I don't think it's a mess. Could you explain why it is a mess?
Thanks for the Due Diligence.
HHSE -- NO DILUTION in over 2.5 years!
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
Looking for cheap shares?
CEO VISION> To understand my vision of Surge, you must think of our interworking subsidiaries functioning as global divisions with the purpose of each generating self-sustaining revenue while leveraging off one another to propel our growth.
We are not building a simple linear company, a project or stock deal. We are focused with a burning desire for this company to be a life changing net worth event for all involved. This effort will be led by a team of extremely smart and already successful individuals. I am leading this team to actively do something to add value to ownership of our stock every single day.
Most importantly, my team executes and finishes exactly what we say we will do.
My top-line vision is to hold a competitive advantage delivering Telecom and FinTech (Financial Technology) products to underserved markets by owning both online and physical merchant network distribution channels. I believe that we must either be in front of customers physically where they shop or to influence them via social media. We now control our destiny in both distribution channels with the subsidiaries you see on this website.
Surge Holdings has complete control of the marketing arm, main distribution channels and the payment mechanisms for its existing products, new products in development and any other profitable products we come across that make both sense and cents.
If you are evaluating Surge, then I want to thank you for your interest. If you are an existing shareholder, then for your support.
I am all-in and committed to the success of this company.
Brian Cox
Chairman/CEO
https://surgeholdings.com/ceo-vision/
Go HHSE. Off to the races.
BLOG: HHSE Theatricals Off-To-The-Races; Form-10, Uplist, Vodwiz Updates
HHSE-DD/Summary: Uplist OTC:QB, Audits/Form-10, SEC-Compliant, No-Dilution, Sony/Cinedigm, VODWIZ:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138890707
Sunday, March 4, 2018
Hannover House strikes Gold over Oscar's Weekend - with Triple-Threat Events!
Greetings HHSE Friends & Followers - while most of Hollywood primped and planned for the Sunday night Oscar's ceremony... Hannover House was hard at work on high-profile events for both GETTING GRACE and DEATH HOUSE... and box office gold has been struck!
First, on Friday night (March 2nd), the highly-anticipated horror-epic, "DEATH HOUSE" opened as a single screen exclusive at the Regency Plant 16 in Van Nuys, CA (a Los Angeles suburb in the San Fernando Valley). The 7:30 show was sold out over a week in advance, and was over capacity with Standing Room Only audience members, and a spill-over into the 9:55-pm showtime. Overall the film hit $10,295 for the three-day weekend... making it the HIGHEST PER SCREEN AVERAGE of any new release this week (beating out Red Sparrow and Death Wish on the per-screen basis - however, both those major studio releases did also have THOUSANDS of locations, so our achievement is quantified in comparison). Still... a win is a win!
http://www.boxofficemojo.com/weekend/chart/
Getty HD Broadcast News shot and edited a terrific piece from the event, which can be viewed here:
http://bit.ly/2HXVXzo
The Getty piece is used as raw material for local TV stations and websites to cut their own stories about DEATH HOUSE, as it opens on March 16 in 25 additional markets. Stills photos from the Associated Press are included near the bottom of this blog.
But that wasn't ALL happening with DEATH HOUSE - On Sunday Night (March 4) - on the birthday of Death House screenwriter GUNNAR HANSEN, another Standing-Room-Only event was held at the Sherman Theatre in Stroudsburg, PA - with over 275 attendees participating in a special event screening and the announcement of the Gunnar Hansen Film Scholarship Fund. Many movie fans will recognize the name GUNNAR HANSEN from his iconic and terrifying role as "Leatherface" in the classic "Texas Chainsaw Massacre." Mr. Hansen passed away from cancer just days before the filming of "DEATH HOUSE," and producer Rick Finkelstein made a death-bed promise to Gunnar that the film would get completed and released.
NEXT - there were SIX significant happenings in the last few days for "GETTING GRACE."
HHSE and Getting Grace Films are pulling NO PUNCHES to make the marketing campaign for this acclaimed, family film (opens MARCH 23) into an EXTREMELY VISIBLE indie release! Here's a few key items from just the past few days:
1). NRB - Director and lead-actor DANIEL ROEBUCK was a speaker at last week's National Religious Broadcaster's convention in Nashville - and also conducted over a dozen Christian-media interviews that will be released during the week leading up to our March 23 theatrical launch.
2). CACHET ENTERTAINMENT - the hugely successful, Christian-specialty distributor and marketing agency behind films such as "God's Not Dead" and "The War Room" has joined the promotions team for "GETTING GRACE." This will be immensely helpful in branding the film to the Christian marketplace, as well as helping Hannover House reach the hundreds-of-thousands of taste-makers and influential leaders in this marketplace.
www,CachetEntertainment.com
3). TOUR BUS - The "GETTING GRACE" tour got two big boosts on Friday with the completion of the FULL SIZE touring Bus... AND... the Director's Winnebago. Both vehicles are prominently "wrapped" with "GETTING GRACE" imagery, and will serve as rolling billboards as the vehicles travel throughout the country over the next two weeks.
4). CHARITY SCREENINGS in LEHIGH VALLEY - Saturday (March 3), saw THREE SOLD OUT special event shows in Allentown and Bethlehem, PA - which raised over $20,000 for local Children's medical charities - and generated a TON of local goodwill, publicity and momentum. "GETTING GRACE" opens on March 23, and in this market, it will be playing at the AMC Allentown 16 and the Regal Northhampton 14 - both locations expected to have opening weekend sold-out shows.
http://www.lehighvalleylive.com/news/index.ssf/2018/03/rolling_out_the_red_carpet_for.html
5). LAUNCH OF 26-CITY TOUR! Immediately after the last of the Saturday Screenings, the "GETTING GRACE" tour hit the road! Promotional stops will hit a total of 26 major markets, and will have "special event screenings" in 15 markets. For locations and showtimes, visit the TOUR tab of the film's website, www.GettingGraceTheMovie.com
6). FIRST SCREENING: BOSTON'S FENWAY! Yes, folks, "GETTING GRACE" screened Sunday night at the Regal Fenway Park 13 Theatre in Boston... with media attendees, taste-makers, and general public meeting the two lead stars, DANIEL ROEBUCK and MADELYN DUNDON.
SO - it looks like both of these new HHSE Theatrical Releases are off-to-the races.
But there's more to report on the corporate front - here's a quick summary:
a). LIBRARY VALUATION - at long last, HHSE has an updated Library Valuation that meets the auditor's requirements! This is an important element for the Form 10 filing as it impacts the company's balance sheet.
b). YEAR-END FILINGS - The Q4 for 2017 is completed and will be filed in a timely manner with the OTC Markets. More importantly, it has been submitted to the outside CPA firm that is checking the formatting and back-up materials needed by the auditors. It is our belief that we can submit the full auditor's package this week.
c). FORM 10 FILING - we believe that the auditors will take about 30-days after receiving these final elements, at which time we will be filing the Form 10 registration statement. The company has engaged a new attorney specializing in S.E.C. filings and disclosures, so that we are minimizing the potential of S.E.C. issues or comments to the Form 10 filing.
d). VODWIZ - The Company has reached an understanding for funding terms with a private investment group for the required financing to complete the VODWIZ website (to the Amazon digital formatting standards), and to upload over 2,500 titles and launch the site and the OTT channel. The timing of the launch is planned to occur immediately prior to the May 9th Cannes Film Festival start - as the VODWIZ site has the capability of delivering content worldwide (titles are restricted by territory based on underlying rights). As the marketplace matures and moves more towards digital streaming, the VODWIZ plan to carry thousands of programs from dozens of indie suppliers (and three major studio suppliers!), is potentially "the tail that wagged the dog" for HHSE revenues and future operations. The funding venture is expected to be documented and executed within the next few days.
e). IRS RESOLUTION - HHSE managers (Parkinson and Shefte) have had two meetings in the last week to resolve the issue of significant over-payment by HHSE of payroll taxes (including penalties and interest). Supporting documentation was provided, and there is an expectation of resolution (acceptance by the IRS) of the totality of payments within the next few days.
Much more to come on all of these matters....
MEDIA NOTE: ANY OR ALL OF THESE DEATH HOUSE IMAGES ARE CLEARED BY HANNOVER HOUSE FOR YOUR REPUBLICATION AND GENERAL RE-USE FOR ARTICLES OR MENTIONS OF THE RELEASE OF "DEATH HOUSE" - Opens in 25+ markets on March 16.
www.DeathHouse.us
http://hannoverhousemovies.blogspot.com/2018/03/hannover-house-strikes-gold-over-oscars.html
Nice Speck: I Believe: Article: "DEATH_HOUSE" Premiere $10,300 Ticket-Sales, Here's Why Important
March 4, 2018
Death House Makes $10,300 In Ticket Sales. Here’s Why That’s Important
After several years of principal photography and post production edits, the critically acclaimed horror-thriller Death House is officially making its way to public screenings. It started on March 2, 2018 with a limited premiere in Los Angeles and Stroudsburg, Pennsylvania following TONIGHT. Based only on that one theater’s total, Box Office Mojo is reporting that Death House made $10,300 in ticket sales during its theatrical debut this weekend. Of course, estimates could be a lot higher before Monday morning. If you consider the average ticket price is $10, that means over 1,000 people went out for the movie people are calling “exciting and unnerving” and “original and intelligent.”
Here’s why these numbers are important. Produced under Entertainment Factory, LLC and sent to theaters by Hannover House, Death House is marginally an independently produced feature film. Hannover House isn’t known for putting any big titles out on the market, so this is a real chance to make Death House their first sleeper hit. We always say, “support independent horror,” but this time we really mean it! Theaters and film distributors are more likely to bump up their screenings and in-house numbers if there’s a demand for the product. On March 9, 2018, Death House is expanding to more locations in Atlanta, D.C., Florida, New York, Texas, and every other major city across America.
Keep the momentum going, folks. Make every turn out count. Every horror fan who sees Death House in theaters increases the chance that it’ll expand further, and the same opportunity to see this movie on the big screen can be provided to another viewer. So much hard work and dedication went into this movie, it would be a shame to miss out on the first Expendables of Horror.
Screening information can be found, here: https://www.facebook.com/DeathHouseHorror/.
Based on the screenplay by Gunnar Hansen and B. Harrison Smith, Death House stars Adrienne Barbeau (The Fog), Kane Hodder (Friday the 13th), Dee Wallace (Cujo), Sid Haig (House of 1000 Corpses), Tony Todd (Candyman), Michael Berryman (The Hills Have Eyes), Barbara Crampton (From Beyond), Sean Whalen (The People Under the Stairs), Vernon Wells (Innerspace), Tiffany Shepis (Sharknado 2), Felissa Rose (Sleepaway Camp), Cortney Palm (Zombeavers), Bill Moseley (Texas Chainsaw Massacre 2), Camille Keaton (I Spit on Your Grave), Tony Moran (Halloween), Debbie Rochon (Slime City Massacre), Brinke Stevens (Slumber Party Massacre), Lloyd Kaufman (Toxic Avenger), R.A. Mihailoff (Texas Chainsaw Massacre 3), Vincent Ward (“The Walking Dead”) and Beverly Randolph (Return of the Living Dead).
Synopsis: During an exclusive tour, a power breakdown inside a secret prison known as the Death House sends two agents fighting through a labrynth of horrors while being pursued by a ruthless army of roaming inmates. As they fight to escape, the agents push toward the lowest depths of the facility where they learn a supernatural group of evil beings are their only chance for survival.
https://www.horrorsociety.com/2018/03/04/death-house-makes-10300-ticket-sales-heres-thats-important/
I Believe
It would be MOST PATHETIC if I followed HHSE for 8 years and I didn't LOVE the company. It would be BEYOND PATHETIC. But fortunately, I'm a big believer that we're looking at the next 1000% winner here"
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
That is an opinion. There is no truth to that at all.
Website re-design is in progress.
https://www.hannoverhouse.com/
It would be MOST PATHETIC if I followed HHSE for 8 years and I didn't LOVE the company. It would be BEYOND PATHETIC. But fortunately, I'm a big believer that we're looking at the next 1000% winner here"
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
"Agree. It would be MOST PATHETIC is I followed HHSE for 8 years and I didn't LOVE the company. It would be BEYOND PATHETIC. But fortunately, I'm a big believer that we're looking at the next 1000% winner here"
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
Hannover House strikes Gold over Oscar's Weekend - with Triple-Threat Events!
Sunday, March 4, 2018
Hannover House strikes Gold over Oscar's Weekend - with Triple-Threat Events!
Greetings HHSE Friends & Followers - while most of Hollywood primped and planned for the Sunday night Oscar's ceremony... Hannover House was hard at work on high-profile events for both GETTING GRACE and DEATH HOUSE... and box office gold has been struck!
First, on Friday night (March 2nd), the highly-anticipated horror-epic, "DEATH HOUSE" opened as a single screen exclusive at the Regency Plant 16 in Van Nuys, CA (a Los Angeles suburb in the San Fernando Valley). The 7:30 show was sold out over a week in advance, and was over capacity with Standing Room Only audience members, and a spill-over into the 9:55-pm showtime. Overall the film hit $10,295 for the three-day weekend... making it the HIGHEST PER SCREEN AVERAGE of any new release this week (beating out Red Sparrow and Death Wish on the per-screen basis - however, both those major studio releases did also have THOUSANDS of locations, so our achievement is quantified in comparison). Still... a win is a win!
http://www.boxofficemojo.com/weekend/chart/
Getty HD Broadcast News shot and edited a terrific piece from the event, which can be viewed here:
http://bit.ly/2HXVXzo
The Getty piece is used as raw material for local TV stations and websites to cut their own stories about DEATH HOUSE, as it opens on March 16 in 25 additional markets. Stills photos from the Associated Press are included near the bottom of this blog.
But that wasn't ALL happening with DEATH HOUSE - On Sunday Night (March 4) - on the birthday of Death House screenwriter GUNNAR HANSEN, another Standing-Room-Only event was held at the Sherman Theatre in Stroudsburg, PA - with over 275 attendees participating in a special event screening and the announcement of the Gunnar Hansen Film Scholarship Fund. Many movie fans will recognize the name GUNNAR HANSEN from his iconic and terrifying role as "Leatherface" in the classic "Texas Chainsaw Massacre." Mr. Hansen passed away from cancer just days before the filming of "DEATH HOUSE," and producer Rick Finkelstein made a death-bed promise to Gunnar that the film would get completed and released.
NEXT - there were SIX significant happenings in the last few days for "GETTING GRACE."
HHSE and Getting Grace Films are pulling NO PUNCHES to make the marketing campaign for this acclaimed, family film (opens MARCH 23) into an EXTREMELY VISIBLE indie release! Here's a few key items from just the past few days:
1). NRB - Director and lead-actor DANIEL ROEBUCK was a speaker at last week's National Religious Broadcaster's convention in Nashville - and also conducted over a dozen Christian-media interviews that will be released during the week leading up to our March 23 theatrical launch.
2). CACHET ENTERTAINMENT - the hugely successful, Christian-specialty distributor and marketing agency behind films such as "God's Not Dead" and "The War Room" has joined the promotions team for "GETTING GRACE." This will be immensely helpful in branding the film to the Christian marketplace, as well as helping Hannover House reach the hundreds-of-thousands of taste-makers and influential leaders in this marketplace.
www,CachetEntertainment.com
3). TOUR BUS - The "GETTING GRACE" tour got two big boosts on Friday with the completion of the FULL SIZE touring Bus... AND... the Director's Winnebago. Both vehicles are prominently "wrapped" with "GETTING GRACE" imagery, and will serve as rolling billboards as the vehicles travel throughout the country over the next two weeks.
4). CHARITY SCREENINGS in LEHIGH VALLEY - Saturday (March 3), saw THREE SOLD OUT special event shows in Allentown and Bethlehem, PA - which raised over $20,000 for local Children's medical charities - and generated a TON of local goodwill, publicity and momentum. "GETTING GRACE" opens on March 23, and in this market, it will be playing at the AMC Allentown 16 and the Regal Northhampton 14 - both locations expected to have opening weekend sold-out shows.
http://www.lehighvalleylive.com/news/index.ssf/2018/03/rolling_out_the_red_carpet_for.html
5). LAUNCH OF 26-CITY TOUR! Immediately after the last of the Saturday Screenings, the "GETTING GRACE" tour hit the road! Promotional stops will hit a total of 26 major markets, and will have "special event screenings" in 15 markets. For locations and showtimes, visit the TOUR tab of the film's website, www.GettingGraceTheMovie.com
6). FIRST SCREENING: BOSTON'S FENWAY! Yes, folks, "GETTING GRACE" screened Sunday night at the Regal Fenway Park 13 Theatre in Boston... with media attendees, taste-makers, and general public meeting the two lead stars, DANIEL ROEBUCK and MADELYN DUNDON.
SO - it looks like both of these new HHSE Theatrical Releases are off-to-the races.
But there's more to report on the corporate front - here's a quick summary:
a). LIBRARY VALUATION - at long last, HHSE has an updated Library Valuation that meets the auditor's requirements! This is an important element for the Form 10 filing as it impacts the company's balance sheet.
b). YEAR-END FILINGS - The Q4 for 2017 is completed and will be filed in a timely manner with the OTC Markets. More importantly, it has been submitted to the outside CPA firm that is checking the formatting and back-up materials needed by the auditors. It is our belief that we can submit the full auditor's package this week.
c). FORM 10 FILING - we believe that the auditors will take about 30-days after receiving these final elements, at which time we will be filing the Form 10 registration statement. The company has engaged a new attorney specializing in S.E.C. filings and disclosures, so that we are minimizing the potential of S.E.C. issues or comments to the Form 10 filing.
d). VODWIZ - The Company has reached an understanding for funding terms with a private investment group for the required financing to complete the VODWIZ website (to the Amazon digital formatting standards), and to upload over 2,500 titles and launch the site and the OTT channel. The timing of the launch is planned to occur immediately prior to the May 9th Cannes Film Festival start - as the VODWIZ site has the capability of delivering content worldwide (titles are restricted by territory based on underlying rights). As the marketplace matures and moves more towards digital streaming, the VODWIZ plan to carry thousands of programs from dozens of indie suppliers (and three major studio suppliers!), is potentially "the tail that wagged the dog" for HHSE revenues and future operations. The funding venture is expected to be documented and executed within the next few days.
e). IRS RESOLUTION - HHSE managers (Parkinson and Shefte) have had two meetings in the last week to resolve the issue of significant over-payment by HHSE of payroll taxes (including penalties and interest). Supporting documentation was provided, and there is an expectation of resolution (acceptance by the IRS) of the totality of payments within the next few days.
Much more to come on all of these matters....
Thanks Speck: FACEBOOK: Sold Out DEATH_HOUSE Premiere Great Audience Reviews
From DEATH HOUSE Facebook Page:
Get ready, horror fans!
Death House got great audience reviews from 2 sold out shows at the West Coast LA premiere last night! Early word is it's a fun 80's midnight style movie and people want to see it again!
Expands nationwide March 9 & 16.
Image may contain: 8 people, people smiling, people standing
https://www.facebook.com/pg/DeathHouseHorror/posts/?ref=page_internal
B Harrison Smith, Death House director talks about the collaboration with Gunnar Hansen
Nice Speck: BLOG: msn Names Hannover House A Leading Company!
It still impresses me that msn has the foresight to recognizes HHSE as a leading company. Once investors wake up (think UPLIST) the stock price will follow.
HHSE-Uplist OTC:QB, Audits/Form-10, SEC-Compliant, No-Dilution, Sony/Cinedigm, VODWIZ, DD/Summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138927294
Wednesday, February 28, 2018
Thank you MSN Money for listing Hannover House as one of the top three Most Notable companies in Arkansas!
Always nice to have the mainstream media recognize the value of the Hannover House brand name!
I guess when you've been operating continuously for TWENTY-FIVE years, and with over EIGHT-MILLION (8,000,000) total published / distributed units sold into the marketplace (books and videos combined), you start to become a known commodity to consumers!
What a great honor to be one of only three companies listed, the others being Walmart Stores, Inc. (arguably the world's largest company based on the dual factors of gross revenues and total employees) and Stephens, Inc., recognized as the largest institutional investor group outside of Wall Street. Two other Fortune 500 companies were skipped over: Tyson Foods and J.B. Hunt... making our designation quite impressive! Go HHSE!
The most famous companies in each state and D.C.
ARKANSAS
Over in Arkansas, one major company rules the roost: Walmart. The planet's biggest retailer is headquartered in the town of Bentonville. Other leading Arkansas-based businesses include private investment bank Stephens and media distributor Hannover House
https://www.msn.com/en-us/money/companies/the-most-famous-companies-in-every-state-and-dc/ss-BBICksA#image=5
http://hannoverhousemovies.blogspot.com/2018/02/thank-you-msn-money-for-listing.html
HHSE
HHSE -- NO DILUTION in over 2.5 years!
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
That doesn't prove that what in progress now is fantasy.
Game on! Feel free to copy/paste to all your friends ...
http://hannoverhousemovies.blogspot.com
https://twitter.com/DeathHouseMovie?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
https://www.gettinggracethemovie.com
https://www.facebook.com/Getting-Grace-403474653165296/
https://www.facebook.com/DeathHouseHorror/
https://twitter.com/getting_grace?lang=en
http://www.imdb.com/title/tt5711672/
http://www.imdb.com/title/tt2984576/
https://www.hannoverhouse.com
Audits/Form-10/Uplist OTCQB Update
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138841795
Quote:
SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES - HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
The electronic registration of HHSE stock shares will require a reconciliation of all outstanding shares.
That will expose the prevalence of short shares, including those naked short shares.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=246008004192114015010151198166073075243058058111
https://www.msn.com/en-us/money/companies/the-most-famous-companies-in-every-state-and-dc/ss-BBICksA#image=5
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
Advertise Here
Sure Trader - $4.95 Per-Trade + 6:1 Leverage
Prove it's fantasy.
http://hannoverhousemovies.blogspot.com
https://twitter.com/DeathHouseMovie?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
https://www.gettinggracethemovie.com
https://www.facebook.com/Getting-Grace-403474653165296/
https://www.facebook.com/DeathHouseHorror/
https://twitter.com/getting_grace?lang=en
http://www.imdb.com/title/tt5711672/
http://www.imdb.com/title/tt2984576/
https://www.hannoverhouse.com
Audits/Form-10/Uplist OTCQB Update
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138841795
Quote:
SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES - HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
The electronic registration of HHSE stock shares will require a reconciliation of all outstanding shares.
That will expose the prevalence of short shares, including those naked short shares.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=246008004192114015010151198166073075243058058111
https://www.msn.com/en-us/money/companies/the-most-famous-companies-in-every-state-and-dc/ss-BBICksA#image=5
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
Prove it.
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
Excellent pba. Thank you!
Game on! Feel free to copy/paste to all your friends ...
http://hannoverhousemovies.blogspot.com
https://twitter.com/DeathHouseMovie?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
https://www.gettinggracethemovie.com
https://www.facebook.com/Getting-Grace-403474653165296/
https://www.facebook.com/DeathHouseHorror/
https://twitter.com/getting_grace?lang=en
http://www.imdb.com/title/tt5711672/
http://www.imdb.com/title/tt2984576/
https://www.hannoverhouse.com
Audits/Form-10/Uplist OTCQB Update
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138841795
Quote:
SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES - HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
The electronic registration of HHSE stock shares will require a reconciliation of all outstanding shares.
That will expose the prevalence of short shares, including those naked short shares.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=246008004192114015010151198166073075243058058111
https://www.msn.com/en-us/money/companies/the-most-famous-companies-in-every-state-and-dc/ss-BBICksA#image=5
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
So glad it got off of the pinks
This drop kinda sucks.
This link may help. Corp Status active.
https://wyobiz.wy.gov/business/FilingDetails.aspx?eFNum=246008004192114015010151198166073075243058058111
Also this may be interesting to anyone looking at HHSE.
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
HHSE - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture.
The SONY relationship includes the opportunity to place Hannover House represented titles into their network of direct distribution divisions in all major territories worldwide.
Status HHSE Audits, Form 10, Uplist To OTCQB
Handling HIGHER PROFILE titles and ORIGINAL PRODUCTIONS. To create better quality titles with the greatest commercial value. End of the micro-budget, direct-to-video market.
2.) NEW DISTRIBUTION PARTNERSHIPS
- Sony Pictures Home Entertainment
- Cinedigm Entertainment
- Random Media (the indie studio headed by former Paramount President Eric Doctorow and indie-film producer Tom Skouras).
3.) HHSE Executve Producers / Worldwide Distributors
- Two different CURRENT Productions.
4.) Two Major Titles In Theatrical Releases.
- a.) "BATTLECREEK"
- b.) "DAISY WINTERS"
5.) Five Genre Titles In Limited Theatrical Releases Soon.
- a.) "BLOODFEAST"
- b.) "CHOSEN"
- c.) "DEATH HOUSE"
- d.) "WHERE'S THE DRAGON?"
- e.) "THE RIOT ACT"
6.) DVD & BluRay New Releases Pipeline (12 Titles, $4,000,000+ Gross Shipments).
"THE LENNON PROJECT", "SACRED HEART", "GETTING GRACE", "BONOBOS" and "ALGERIAN" (now renamed as "SLEEPER CELL"), as well as the romantic comedy "SPICES OF LIBERTY", the Red Bull motorsports actioner "RIDE UNITED", and the also long-awaited "DINOSAURS OF THE JURASSIC". Other home video titles include the thrillers "IDENTITY CRISIS", "MUSE" and "INSOMNIUM".
7.) VODwiz - Online Independent Films Streaming Portal
* Doubled Film Titles In Library (Second only to Amazon at this point).
* VODWIZ has now partnered with Amazon Digital Services for hosting, operations, payment processing and customer service of all activities.
* VODWIZ site now being assembled, prepared and uploaded will feature THREE main categories of programming on the home-page menu:
A.) WATCH - Thousands of feature films and television episodes
B.) LEARN - Educational Programming, Many subjects and achievement levels.
C.) PLAY - Single-player, interactive and group-play VideoGames
* Two User Options:
a.) Pay-Per-Transaction
b.) Monthly Subscription Models
* HHSE initial (first year) target is to have 100,000 subscription customers, averaged at $8.50 per month - for annualized gross revenues of $10.2-million.
8.) New HHSE Staff Hires:
- Tom Sims to Become President of VODWIZ, INC.,
- Engagement of EARL HALE as Technical Services Director for VODWIZ and Hannover House. Earl has an impressive resume in video production, mastering and technical services, including multi-year directorships at Walmart TV and the Media Center of the University of Arkansas Global Campus.
- Desiree Garnier as our Director of Marketing.
9.) Two Major Financing Agreements of Epic Productions (Transform HHSE Profile & Revenues).
- a.) "MOTHER GOOSE"
- b.) "MELTDOWN"
10.) HHSE engaged two professional service advisors to assist Form 10 & Uplist OTCQB.
- CPA Lisa Lashley Higgins has been engaged to review the company's books, records and financial filings covering the years 2015, 2016 and 2017, and to verify compliance with the needs set forth by the company's auditors.
- Attorney Steven H. Kay has been engaged to provide general transactional legal counsel, as well as filings relating to the elimination of contestable debts and prior litigation matters.
11.) HHSE Corporate Governances
* Updated TV & Films Library Valuation
* Audited 2016, 2017 Financials
* SEC Form 10 Registration
* SEC Review (60 Days Maximum)
* HHSE Uplist to OTCQB
/8/18 HHSE Filing - 3rd Quarter Report
Q3 Revenues $351,252 Net Income $100,594
1/5/18 HHSE Press Release:
"HHSE Engages Two Advisors To Perform Form 10, Uplist OTCQB Duties"
1/4/18 Two HHSE IR BLOGS:
HHSE Engages Counsel To Dispute Frivolous Lawsuits & Erroneous Debts; Q3 Soon
1/2/18 HHSE IR BLOG:
Preparing 2016/2017 Financials For CPA/Audits, Form_10, Uplist-OTCQB
12/29/17 HHSE Press Release:
Hannover House Epic Horror Feature "DEATH HOUSE" Theatrical Release February 23
12/23/17 HHSE IR BLOG:
HHSE Past, Present, Future
11/22/17HHSE IR BLOG
HHSE NEEDS To UPLIST, but No Dilution By Way Of Merger Required
10/23/17 HHSE IR BLOG
HHSE Board of Directors Approves UPLISTING, Form 10 Costs & Implementation
10/22/17 HHSE IR BLOG
HHSE Maturation "To The Next Level" Already Well Underway
Nice pba!
The Superbowl of HHSE Blog Updates!
Greetings HHSE Friends & Followers - As many of you plan to watch the Superbowl today, we will do our best to keep this post concise. But it won't be easy: there are so many positive activities in motion! So without further delay, here's the CLIFF NOTES abbreviated summary:
1). UPLIST REGISTRATION - The dissolution with Crimson Forest will be completed this week, with a formal termination document that has been mutually approved, and a series of short-form terminations for the individual title agreements (as some had different licensors than Crimson Forest Entertainment Group, Inc.). This will also trigger the long-requested removal of HHSE management names off the Nevada Secretary of State listing as corporate officers. Part of the overall settlement with CRIM involves the reversion of rights in "Where's the Dragon" back to the original licensors... which is why this item has not appeared on any of the HHSE release schedules for the past four months. With the Crimson merger obstacle removed, the next steps for our uplist are as follows:
a). PRE-AUDIT - Completion of formatting and overview by outside CPA - covering 2015 Tax Returns, and the full years of 2016 and 2017. This step is expected to be completed this week, with the results handed over (along with the remainder of the audit materials) to our PCAOB firm.
b). UPDATED LIBRARY REPORT - This step is expected to be completed by Feb. 26, and provided to the auditors as the last item for full delivery.
c). REDRAFTED FORM 10 REGISTRATION - This is already completed, awaiting review by outside S.E.C. counsel, and the auditor's letters.
d). TIMING - Once filed with the S.E.C., the registration becomes effective on the earlier of 60 days, or S.E.C. approval. This will trigger our uplist to OTC: QB and the activation of stock share transfers electronically through the DTC. Management believes that being fully registered, and uplisted away from the Pinksheets, will spark a wave of new investors and funds.
2). CURRENT RELEASE ACTIVITIES - So much to report, but here are the highlights:
a). BATTLECREEK hits most major retailers this TUESDAY (Feb. 6) - and is already the company's largest new release "shipped" item in five years. Based on current pre-orders with Amazon.com, which are STRONG (actually 10-X stronger than last year's top video, "Lost in the Pacific"), we are hopeful that this consumer interest will also apply to Walmart, K-Mart, Target, Best Buy and other locations. Check out this film, it's worth the modest purchase price!
https://www.amazon.com/Battlecreek-Bill-Skarsg%C3%A5rd/dp/B077Y6CLXJ/ref=sr_1_1_twi_dvd_1?s=movies-tv&ie=UTF8&qid=1517787440&sr=1-1&keywords=battlecreek
b). BLOODFEAST - A limited release of "R" rated DVDs and BluRays will also hit selected retailers on Tuesday... but the BIG GUNS will be blasting with our "SPECIAL, UNRATED AND UNEDITED DIRECTOR'S CUT" - which is rolling out "only in theatres" on a city by city basis. Management believes that the hard-core Horror fans will support this Unrated version, and thus far, the response from the specialty media supports this belief.
https://www.amazon.com/Blood-Feast-Robert-Rusler/dp/B077YPK5KM/ref=sr_1_sc_8?s=movies-tv&ie=UTF8&qid=1517787521&sr=1-8-spell&keywords=bloodfeast
c). DEATH HOUSE - opens in theatres Feb. 23 - this deserves an entire mega blog to itself. For now, we'll include the new trailer link.
https://www.youtube.com/watch?v=Op3-zafK_0U
d). GETTING GRACE - opens in theatres March 23, and is already proving to be the company's top theatrical title, probably of all time (several "sneak peek" screenings have already occurred and SOLD OUT, with literally thousands of tickets cumulatively already sold!). This title deserves two or three mega-blogs. But for now, we'll include just a few images and a link or two.
Trailer # 1 (long version): https://www.youtube.com/watch?v=l9EGeSSUCYI
"When Audiences Get Grace" (short film after one of many sold-out sneak peek events):
https://vimeo.com/247897969
EVENT BRITE - Notification of THREE MORE sold out shows, after only 3-days of tickets going on sale!
https://www.eventbrite.com/e/getting-grace-lehigh-valley-charity-premiere-tickets-42617096884
https://www.eventbrite.com/e/getting-grace-lehigh-valley-charity-premiere-tickets-42617096884#tickets
Oh... and did we forget to mention the 26-city BUS TOUR prior to the theatrical opening? Or the National Religious Broadcasters (NRB) promotion in Nashville? Or the first-time-ever that the Children's Miracle Network has cross-promoted a theatrical release film? There's so much more to the Getting Grace release campaign, that other blog(s) would be required!
e). QUIETUS - Retail support for this Feb. 27 long-anticipated re-release (and HHSE's first release of this item in Quality Trade Cover format), continues to build. Shown below is the FULL PAGE ad for the Feb. 12 issue of PUBLISHER'S WEEKLY, the trade industry guide reaching 68,000 book industry professionals and book stores each week. Also below is the Amazon.com product link...
Many top reviewers have described QUIETUS as a literary masterpiece... so get a copy and find out for yourself why major retailers such as Barnes & Noble, Books-A-Million and Hudson Group are presenting this book - first released in 2002 - back on the New Release shelves!
https://www.amazon.com/Quietus-Vivian-Schilling/dp/1640080449/ref=sr_1_1?ie=UTF8&qid=1517785698&sr=8-1&keywords=Vivian+Schilling
3). SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES - HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
The initial titles that will benefit under this new distribution pact are: DAISY WINTERS, THE ALGERIAN and BONOBOS: BACK TO THE WILD. There are other notable developments in motion with BONOBOS that will merit a separate blog or press announcement. But for now, here's a link to a behind-the-scenes look at the production of this film, and the woman behind the Lola Ya Bonobo Sanctuary in Africa:
https://www.youtube.com/watch?v=P6GxlA-pKwI
Some HHSE longs will recognize that both ALGERIAN and BONOBOS were summer, 2015 theatrical releases for Hannover House. These items were held-back from Home Video release initially due to the prior merger with Crimson, but more recently due to the expectation of greater sales upside that may be obtainable through the Sony sales network.
4). VODWIZ - There's so many exciting developments and updates for us to cover on this venture - that even a Cliff Notes summary at this time cannot do it justice. Stay tuned for separate news on this topic!
Who Will Win the SUPERBOWL Today? Hard to predict... but it's not hard to predict that HHSE has reached a significant turning point in the company's history!
MORE TO FOLLOW>>>>!
Posted by HHSE at 3:52 PM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Thursday, January 11, 2018
Yowsa! Mega-Success of "IT" video release spurs THOUSANDS of new orders for HHSE's BATTLECREEK!
Dear HHSE Friends & Followers - This Tuesday was the Video release date for the blockbuster theatrical hit "IT" - starring Bill Skarsgård as the super-scary clown. Consumer response for "IT" has been so substantial that Hannover House has already received new orders for multiple thousands-of-units of "BATTLECREEK" (street date Feb. 6), also starring Bill Skarsgård! The momentum might get even stronger with the February launch of Bill's new TV series, "CASTLE ROCK" from J.J. Abrams, Stephen King and HULU. With "BATTLECREEK" right in the middle of a media-feeding-frenzy for Bill Skarsgård - this title looks to be positioned as a very successful video release for Hannover House!
Posted by HHSE at 1:24 PM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Thursday, January 4, 2018
HHSE Engages Counsel to Dispute Fraudulently Obtained Judgments, and other updates
Greetings HHSE Friends & Followers - As a component of our move to clean-up our balance sheet and shed the company of frivolous lawsuits and erroneous debts, HHSE has engaged the Law Firm of Steven H. Kay Associates in Fayetteville, Arkansas. Mr. Kay will be filing motions to initially "freeze" collection efforts by BEDROCK VENTURES and JSJ INVESTMENTS - based on the fraudulent nature of the underlying claims and the "foreign judgment" status that can be contested and adjudicated under Arkansas Law for foreign default judgments (i.e., defaults obtained in states other than Arkansas). HHSE Shareholders may recall that we pursued this same strategy with TCA Global Master Fund - a company that is often considered to be the nuclear bomb of Predatory Lenders - and HHSE prevailed under Arkansas Law.
HHSE Shareholders might also recall that Steven H. Kay was counsel for HHSE recently in the case against Amityville Asylum producers filing a frivolous claim for "projected" amounts due. It was HHSE position that the producers were only due the amounts per the terms of the contract... not a projected amount that the producer "felt" the movie "might have earned." The claim for more than $300,000 by Amityville was reduced to the actual balance of $17,000 and change, which was the outcome that HHSE successfully sought to obtain.
HHSE Shareholders may also recall that "stock short-sellers" were crying "sky is falling, the end is near" with the Amityville lawsuit filing, in hopes of persuading emotional sellers to dump HHSE stock last summer. Again, we remind all shareholders to refer to HHSE filings and this blog for legally accurate information and full disclosures, as opposed to paying any attention to the drunken mumblings of anonymous chat-board short-sellers. These naysayers know that their days of having any impact against HHSE are short-numbered, as our Form 10 registration will elevate the access of the company's stock to a much wider base of investors - thus minimizing the impact of self-serving, chat-board chatter.
Regarding BEDROCK, due to breached commitments for funding the company that were the basis of a massive stock issuance by HHSE to Bedrock, HHSE counsel feels that this California judgment filing has a solid basis to be contested, adjudicated and won in Arkansas Courts.
Regarding JSJ INVESTMENTS, the refusal of JSJ to accept cash plus interest in full (per the terms of the note), but instead to sue for more than three-times the amount on the pretense that "they were always entitled to shares, not 'just' repayment" renders the note usurious and illegal under the laws of virtually every state. Counsel, therefore, feels that a motion to freeze collection efforts and to re-open the claim so that it can be adjudicated, is a likely result for HHSE.
In other corporate governance matters, the company has renewed it's various corporate filings with the Secretary of State offices in Wyoming and Arkansas (an annual house-keeping matter of a simple filing). The company has also received confirmation from the IRS that the full payroll tax liabilities that were the subject of a prior lien have been fully paid, and that a reconciliation of the revised amount of interest and penalties (also paid) shall be issued shortly and submitted to all HHSE customers receiving levy letters. HHSE has since engaged a payroll service to handle the monthly 941 and tax paperwork filing requirements.
All of these steps are elements of the Form 10 Registration that the company is planning to file in the upcoming weeks... and to set off 2018 as an epic year for our loyal and fully informed shareholders!
Onward....
Posted by HHSE at 8:52 AM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Tuesday, January 2, 2018
Update on corporate filings
Happy New Year to HHSE Friends & Followers. Here's a couple of quick updates on corporate filings.
1). Q3 filings will be submitted to the OTC Markets tomorrow - this should restore the company's "current" status. UPDATE: THURS., JAN. 4 - The annual HHSE subscription to the OTC Markets had expired and had to be renewed (which occurred on Tuesday); However, OTC MARKETS client services told HHSE this morning that the company's access to post reports (currently Q3), will be activated within the next day or two.
2). Q4 filings will be completed by Monday and provided (along with full 2017 results) to the outside CPA firm conducting the Pre-audit review.
3). Upon completion of the Pre-audit review, HHSE will submit the full 2016 and 2017 packages to our auditors in preparation for the stock registration filing.
4). Annual corporate governance filings (with applicable Secretary of State and Registered Agents) will also occur this week.
Watch for press news on new releases and distribution updates this week and next week. Very exciting times....
Posted by HHSE at 11:53 AM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Saturday, December 23, 2017
Where we have been... Where we are now... and Where we are going at HHSE...
Greetings HHSE Friends & Followers:
As we reflect back on 2017, HHSE Management is taking a few days to look at our past, present and future activities to help guide sage decisions. 2017 has been a momentous year for the company - due in large part to the attempted (but terminated) merger with Crimson Forest, and the subsequent re-focus of the company's primary activities and revenue streams.
Looking much further back - five, six, seven years and more - and looking forward in time for an equal time-frame, we can see trends and opportunities for HHSE and our shareholders.
First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.
As a result of this general trend for Pinksheet companies, a whole sub-industry of stock manipulators has developed that can impact OTC-Pinksheet listed companies (for the entirety of OTC markets in general, not specifically limited to Hannover House). Like a gang of drunken hobos in public park - mumbling to each other with insane prognostications - the stock hobos are only effective against low-information shareholders gullible enough to actually read the chat-board postings of manipulative and fact-free ramblings.
Fortunately, every false statement made by the stock hobos or those manipulators attempting to "box" or otherwise control the HHSE stock price, can be easily countered with demonstrable facts.
So, let's take a few minutes to take a high-altitude look at the Company and where we are going.
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initial theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS"); in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart - The chart below is divided into two sections. The top section shows the "approximate market cap" at six-month intervals beginning in June 2010 and continuing through to this week. The Market Cap was calculated by the total of all shares in issue, multiplied by the closing price of the stock during a one-week period during the stated month. The bottom section of the chart shows the total SHARES IN ISSUE for the company during this same time frame. The dark-blue shares represent those that are "restricted" from sale, and the light-blue shares represent the total share count of restricted plus unrestricted shares for that time period.
Perhaps the most visible trends to see on this chart are that the company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!
Posted by HHSE at 11:11 PM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Thursday, December 21, 2017
HHSE VODWIZ welcomes Production Master Technician EARL HALE to our Team!
Greetings Hannover House Friends & Followers - Just in time for the Holidays, we are pleased to announce the engagement of EARL HALE as Technical Services Director for VODWIZ and Hannover House. Earl has an impressive resume in video production, mastering and technical services, including multi-year directorships at Walmart TV and the Media Center of the University of Arkansas Global Campus. A formal press release will post in early January, along with VODWIZ supplier and status news.
Watch this blog for an informative overview on Saturday of Hannover House for the past two years, as well as a sneak-peek into major activities for the company in 2018!
Posted by HHSE at 8:02 AM
Email This
BlogThis!
Share to Twitter
Share to Facebook
Share to Pinterest
Monday, December 4, 2017
Successful Initial Launch of DAISY WINTERS to theatres across the USA!
Good morning HHSE Friends & Followers - We again thank our principal theatrical release partner, REGAL ENTERTAINMENT GROUP for their support with locations and promotional assistance for the current theatrical launch of "DAISY WINTERS." We are honored to have the title on the RegMovies.com HOME PAGE as one of three featured title banners (see screen grab below) - with a campaign that will reach 3.5-million viewers this week. We are also honored that Regal has done theatre-specific FaceBook promotions for DAISY WINTERS, creating another million+ consumer impressions. If you have not yet seen this impressive film, check out showtimes at RegMovies.com, or go to: www.DaisyWintersFilm.com. It's an inspiring, touching and enlightening film, the likes of which Hannover House has never before handled. Check it out!
Home Page screen grab of www.RegMovies.com
Theatre personnel putting up the DAISY WINTERS vinyl banners (next to Star Wars!?)
Daisy Winters posters illuminate nicely inside of theatre light-boxes.
SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES -
HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
The initial titles that will benefit under this new distribution pact are: DAISY WINTERS, THE ALGERIAN and BONOBOS: BACK TO THE WILD. There are other notable developments in motion with BONOBOS that will merit a separate blog or press announcement. But for now, here's a link to a behind-the-scenes look at the production of this film, and the woman behind the Lola Ya Bonobo Sanctuary in Africa:
Some HHSE longs will recognize that both ALGERIAN and BONOBOS were summer, 2015 theatrical releases for Hannover House. These items were held-back from Home Video release initially due to the prior merger with Crimson, but more recently due to the expectation of greater sales upside that may be obtainable through the Sony sales network.
HHSE-Useful Links:
1). UP THE CREEK LINK: https://www.amazon.com/Up-Creek-Tim-Matheson/dp/B005TMXZ0Q
2). CURRENT FILINGS LINK: https://www.otcmarkets.com/financialReportViewer?symbol=HHSE&id=185294
(Shefte's Board Membership is specified on Page 19... nothing has changed).
3). BOX OFFICE MOJO CALENDAR LINK: http://www.boxofficemojo.com/schedule/
(Death House is Feb .23 / Getting Grace is March 23).
4). AMAZON.COM LINK FOR BATTLECREEK VIDEOS: https://www.amazon.com/Battlecreek-Blu-ray-Bill-Skarsg%C3%A5rd/dp/B077Y86FFP/ref=sr_1_1?ie=UTF8&qid=1516995564&sr=8-1&keywords=battlecreek+bill+skarsgard
(WOW! Amazon has it on their top 500 best-sellers list!)
5). AMAZON.COM LINK FOR BLOODFEAST VIDEOS: https://www.amazon.com/Blood-Feast-Blu-ray-Robert-Rusler/dp/B078D75JVF/ref=sr_1_sc_16?s=movies-tv&ie=UTF8&qid=1516995616&sr=1-16-spell&keywords=bloodfeast+movie
(Currently unavailable due to theatrical activities... but isn't this "third party verification"?)
Very Nice. Thanks ds22.
HHSE is on the move up, we can see the increase in the quality and the quantity of the films being distributed and they just announced a distribution partnership with Sony Home Entertainment. Hannover House doing business with some of the big players in the movie distribution business. As a long or a potential new investor this should really catch your attention:
Quote:
3). SONY PICTURES HOME ENT. & DISTRIBUTION STRATEGIES - HHSE has been working for over a year now with industry veteran ERIC DOCTOROW, who is best known for his 20+ years as President of Paramount Home Entertainment (a $-Billion+ Division), and more recently as C.E.O. of Random Media. Many current and upcoming HHSE titles will enjoy the distribution support through SONY as well as Video-On-Demand with The Orchard, and for selected titles, worldwide distribution with Sony Pictures International. HHSE / Medallion are maintaining the existing distribution pacts with other wholesalers - most notably Cinedigm. But for eligible and qualifying titles, the distribution access into Sony's powerhouse field sales force and distribution pipeline is something of a material development for HHSE. This move enables HHSE Management to focus on productions, acquisitions and theatrical release activities - and turn over the distraction and difficulties of home video distribution (as well as the cash-flow drain of video manufacturing and freight) to be handled under more beneficial terms.
Head Clown. Good post. Not your average OTC.
First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.
HHSE -- NO DILUTION in over 2.5 years!
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
“GETTING GRACE” Moneymaker
BLOG-9/11/17: "GETTING GRACE" Wins-All-Top-Four Categories NYC-Metro Film Festival
Monday, September 11, 2017
GETTING GRACE wins all top four categories at NYC-Metro Film Festival
HHSE Congratulates our good friend, actor-director DANIEL ROEBUCK on your victorious SWEEP of all four top awards this past weekend at the NORTHEAST FILM FESTIVAL (NYC- NJ Metro). WOW! What a great way to launch your inspiring movie! GETTING GRACE... well, I guess they GOT it!!!
AUDIENCE FAVORITE
BEST ACTRESS
BEST DIRECTOR
BEST FEATURE
http://www.nefilmfestival.com/
http://hannoverhousemovies.blogspot.com/2017/09/getting-grace-wins-all-top-four.html
HHSE
Where we have been... Where we are now... and Where we are going at HHSE...
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
What else is worth noting for this long, holiday weekend? Here are a few observations:
1). Hannover House has Not Issued any Shares in 2.5-years.For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
5). Thoughts on the HHSE Stock Chart: (abbreviated) The company did very little in share issuances for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog.
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
HHSE CEO Eric Parkinson Accomplishments (Integrity, Professional, Shareholder-Friendly)
When the HHSE CEO Biography was compiled, someone requested some accomplishments while at HHSE. Below, are several actions that demonstrate Mr. Parkinson dedication to being a Professional and Share Holder Friendly. This list is not all inclusive. They have occurred over the last 8 years. They are factual, though for brevity, no links included, though many long term shareholders can both verify and provide Due Diligence.
* HHSE CEO Eric Parkinson and President Don Shefte together owned the HHSE Films & Television Library later valued at $24,276,709. Yet, the officers in exchange for some HHSE shares, transferred the Library to HHSE Treasury (Balance Sheet) to benefit all HHSE shareholders.
* HHSE (TDGI at that time) inherited Authorized Shares 10,000,000,000. HHSE Management Voluntarily Reduced AS to 800,000,000. (10 Billion (not necessary) down to 800 Million).
*HHSE Management owns Preferred Stock which has no Monetary Value, Voting Rights Only.
* HHSE Management Voluntarily Surrendered into HHSE Treasury Substantial Amount Common Shares, Pending a Future Performance Review.
* HHSE Management Voluntarily Each Reduced Annual Salary from $180,000 down to $90,000.
* HHSE Management has received very little actual salary. Vast majority (about $750,000) of salaries are accrued and deferred.
* No Dilution in 2 1/2 Years. No Plans To Ever Again.
* HHSE public existence for 32 full Quarters, has 32 Consecutive Quarters of Revenue & Profits.
* New Distribution Partnerships (Sony, Cinedigm, Random Media).
* HHSE Films & Television Library Valuation currently being updated (should be $28,000,000+).
* Poised to Launch VODwiz - Online Independent Films Streaming Portal.
* Robust 2018, 2019 Theatricals & Original Productions & Home Video New Releases Pipeline.
* HHSE Management currently guiding HHSE to Audited Financials, Form 10 SEC Registration, Uplist to OTCQB.
1). UP THE CREEK LINK: https://www.amazon.com/Up-Creek-Tim-Matheson/dp/B005TMXZ0Q
2). CURRENT FILINGS LINK: https://www.otcmarkets.com/financialReportViewer?symbol=HHSE&id=185294
(Shefte's Board Membership is specified on Page 19... nothing has changed).
3). BOX OFFICE MOJO CALENDAR LINK: http://www.boxofficemojo.com/schedule/
(Death House is Feb .23 / Getting Grace is March 23).
4). AMAZON.COM LINK FOR BATTLECREEK VIDEOS: https://www.amazon.com/Battlecreek-Blu-ray-Bill-Skarsg%C3%A5rd/dp/B077Y86FFP/ref=sr_1_1?ie=UTF8&qid=1516995564&sr=8-1&keywords=battlecreek+bill+skarsgard
(WOW! Amazon has it on their top 500 best-sellers list!)
5). AMAZON.COM LINK FOR BLOODFEAST VIDEOS: https://www.amazon.com/Blood-Feast-Blu-ray-Robert-Rusler/dp/B078D75JVF/ref=sr_1_sc_16?s=movies-tv&ie=UTF8&qid=1516995616&sr=1-16-spell&keywords=bloodfeast+movie
(Currently unavailable due to theatrical activities... but isn't this "third party verification"?)
6). AMAZON.COM LINK FOR QUIETUS BOOK RE-RELEASE: https://www.amazon.com/Quietus-Vivian-Schilling/dp/1640080449/ref=sr_1_1?s=movies-tv&ie=UTF8&qid=1516995702&sr=8-1&keywords=9781640080447
Why is everyone selling?
Just stop. This was explained to you.
"Because the old ownership handed out shares like candy, thus legacy selling is at hand. If you got free shares or shares at .10 cents, would you not take some off the table ? Of course you would. That said, the stock has handled these legacy issues like a champ and this issue will not define new ownership whatsoever. I expect great things from Brian Cox ........ "
Yes. This Rocks! Congratulations SURG OTCQB
https://www.otcmarkets.com/stock/SURG/news
https://globenewswire.com/news-release/2018/02/15/1348912/0/en/Surge-Holdings-Inc-Has-Been-APPROVED-for-Trading-on-the-OTCQB-Venture-Market.html
Las Vegas, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Surge Holdings, Inc. (OTCQB:SURG) a company whose subsidiaries operate in various sectors including Blockchain Fintech Software, Telecommunications, Social Media Marketing and Cryptocurrency Mining; announced today that the Company met the eligibility requirements and has been approved to upgrade to the OTCQB Venture Market.
“We expect this milestone to raise a greater and broader awareness of Surge that will increase trading liquidity and expand our shareholder base,” stated Brian Cox, CEO of Surge Holdings Inc. “We will continue to take steps to engage our existing and potential investors with transparency and sincerity.” added Cox.
OTCQB is the market of choice for early-stage and developing U.S. and International companies. Companies who trade on the OTCQB are required to remain current in their reporting and undergo an annual verification and management certification process. These standards provide improved investor confidence through verified information, as well as greater information availability for investors with Real Time Level 2 quotes.
Cox also said “Our team is happy but not content to reach this goal so early in 2018. We will now focus on finalizing our reorganization in order to achieve the target of holding 4 high revenue and profitable subsidiaries in Blockchain Software, Telecom, Social Media Marketing and Mining Cryptocurrency Assets.”
For more information, go to surgeholdings.com and subscribe to the Instant News Alerts in addition to real-time Company information and market updates, news, blogs, investor relations materials, and more.
Good reading here: https://seekingalpha.com/instablog/384824-joenatural/5103134-surge-holdings-developing-blockchain-story-already-profitable
You seem to be firing warning shots here Yogi. Come on out and tell us what you're thinking. Or did I miss that already?
For your reading pleasure:
https://seekingalpha.com/instablog/384824-joenatural/5103134-surge-holdings-developing-blockchain-story-already-profitable
Head Clown. Good post. Not your average OTC.
First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.
HHSE -- NO DILUTION in over 2.5 years!
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
Thanks for this. GETTING GRACE
GETTING GRACE - opens in theatres March 23, and is already proving to be the company's top theatrical title, probably of all time (several "sneak peek" screenings have already occurred and SOLD OUT, with literally thousands of tickets cumulatively already sold!). This title deserves two or three mega-blogs. But for now, we'll include just a few images and a link or two.
Trailer # 1 (long version):
Great post Head Clown
BLOODFEAST - A limited release of "R" rated DVDs and BluRays will also hit selected retailers on Tuesday... but the BIG GUNS will be blasting with our "SPECIAL, UNRATED AND UNEDITED DIRECTOR'S CUT" - which is rolling out "only in theatres" on a city by city basis. Management believes that the hard-core Horror fans will support this Unrated version, and thus far, the response from the specialty media supports this belief.
https://www.amazon.com/Blood-Feast-Robert-Rusler/dp/B077YPK5KM/ref=sr_1_sc_8?s=movies-tv&ie=UTF8&qid=1517787521&sr=1-8-spell&keywords=bloodfeast ;